Nagahisa Yoshio, Imai Shiro, Yamaguchi Kazushige, Okabe Michio, Tsuruta Atsushi, Kawamoto Kazuyuki, Niwano Mototaka, Sano Kaoru, Park Taebun, Yoshida Yasuo, Ito Tadashi, Ogasahara Keizo
Department of Surgery, Kurashiki Central Hospital.
Gan To Kagaku Ryoho. 2007 Sep;34(9):1501-3.
In February, 19 9 8, a 48-year-old female patient underwent an operation for breast cancer. In November 2003, abdominal MRI revealed metastatic lesions in S 3 and S 5 of the liver, and chemotherapy (trastuzumab+weekly paclitaxel) was started, after which the metastatic lesions quickly reduced in size. No lesions could be detected by April 2004, and she was diagnosed as a complete response (CR). She now visits our hospital as an outpatient without any evidence of recurrence or any side effects of chemotherapy for 8 years and 8 months after surgery. For advanced breast cancer, there is no standard criteria regarding the time when to stop chemotherapy after obtaining a CR. This time, we experienced a case of liver metastasis of breast cancer responding to a regimen of trastuzumab plus weekly paclitaxel chemotherapy maintaining CR for a long period. We discuss the timing of the termination of chemotherapy in such a case in light of our experience and the literature.
1998年2月,一名48岁女性患者接受了乳腺癌手术。2003年11月,腹部磁共振成像(MRI)显示肝脏S3和S5有转移病灶,遂开始化疗(曲妥珠单抗+每周一次紫杉醇),此后转移病灶迅速缩小。到2004年4月已检测不到病灶,她被诊断为完全缓解(CR)。术后8年8个月,她现作为门诊患者前来我院就诊,无任何复发迹象及化疗副作用。对于晚期乳腺癌,在获得完全缓解后何时停止化疗尚无标准标准。此次,我们遇到一例乳腺癌肝转移患者,对曲妥珠单抗加每周一次紫杉醇化疗方案有反应,并长期维持完全缓解。我们根据自身经验和文献讨论了这种情况下化疗终止的时机。